|
|
|
|
EmendTMCnet ...world-renowned US pharmaceutical maker, recently won the silver award of the National Quality Awards for Biotechnology and Medicine Industry for Emend, an anti ... Emend® Approved for Prevention of Moderate Chemotherapy ... Jan 12, 2006 Cancer Consultants (press release), The Food and Drug Administration (FDA) recently added another indication to the antinausea drug (antiemetic) Emend® (aprepitant) for patients with cancer ... FDA Approves EMEND(R) (aprepitant), in Combination with Other ... Jan 11, 2006 Business Wire (press release), ...announced today that the Food and Drug Administration (FDA) has approved EMEND(R) (aprepitant) for use with other antiemetic medicines for the prevention of ... FDA Approves EMEND® (aprepitant), in Combination with Other ... Jan 11, 2006 Biotech Intelligence (press release), ...announced today that the Food and Drug Administration (FDA) has approved EMEND® (aprepitant) for use with other antiemetic medicines for the prevention of ... NJ Business briefs Jan 12, 2006 NorthJersey.com, ...said Wednesday that its anti-nausea drug Emend has been approved for use by a wider range of cancer patients undergoing chemotherapy. ... Genzyme Names New Head of Product Development for Campath and ... Jan 13, 2006 Financial News USA (press release), ...(NYSE:MRK) said Wednesday that the Food and Drug Administration approved its nausea treatment Emend for cancer patients who are undergoing chemotherapy. ... FDA approves nausea drug for cancer patients Jan 12, 2006 The Advocate, The Food and Drug Administration on Wednesday approved Merck’s antinausea medication Emend for use in conjunction with other antinausea drugs to treat cancer ... Meck OK'd for wider use of nausea drug Jan 11, 2006 United Press International WHITEHOUSE STATION, NJ, Jan. 11 (UPI) -- Merck said Wednesday it is OK'd for expanded use of Emend (aprepitant) to prevent nausea/vomiting from chemotherapy. ... UPDATE 1-FDA widens approved use of Merck nausea drug Jan 11, 2006 Reuters NEW YORK, Jan 11 (Reuters) - Merck & Co. (MRK.N: Quote, Profile, Research) on Wednesday said US regulators had approved wider use of its drug Emend, which is ... Business news in brief from around New Jersey Jan 11, 2006 Newsday, ...caused by chemotherapy. The product, Emend, is an oral treatment used in combination with other antiemetic medicines. The approval ... HUGIN NEWS/ANGUS MACLEOD NAMED DIRECTOR OF MEDICINAL CHEMISTRY AT ... Jan 10, 2006 Frankfurter Allgemeine Zeitung, ...of programs leading to clinical candidates, including the Substance P antagonist program that resulted in the marketed product aprepitant (Emend®), and a GABA ... Merck Unveils Plan to Reclaim Leadership Position Dec 15, 2005 Business Wire (press release), ...billion Other reported products* $5.9 to $6.2 billion * Other reported products comprise: AGGRASTAT, ARCOXIA, CANCIDAS, COSOPT, CRIXIVAN, EMEND, INVANZ, MAXALT ... Federal Grant Funds Research on Novel HIV Therapy Dec 19, 2005 PR Newswire (press release), ...of Medicine at the University of Pennsylvania Medical School, will be a phase 1 (safety) trial of the NK-1R antagonist aprepitant (trade name Emend) in adults ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |